Tang Jianfei, Shen Longxiang, Song Sa, An Zhiquan, Zhang Changqing
Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, 600 Yishan Road, Shanghai, 200233, China.
Tumour Biol. 2014 Jan;35(1):779-84. doi: 10.1007/s13277-013-1106-3. Epub 2013 Aug 27.
There are several studies published to assess the associations of murine double minute 2 (MDM2) genetic polymorphisms with risk of malignant bone tumors, but they reported contradictory results and failed to confirm a strong and consistent association. To assess the evidence regarding the associations of MDM2 genetic polymorphisms with the risk of malignant bone tumors, we conducted a meta-analysis of epidemiological studies. The pooled odds ratio (OR) with its 95% confidence intervals (95% CI) was used to assess these possible associations. Four studies with a total of 3,958 individuals were finally included the meta-analysis. Meta-analysis of two studies on MDM2 SNP309 polymorphism showed that MDM2 SNP309 polymorphism was associated with an increased risk of malignant bone tumors (G versus T: OR = 1.72, 95% CI 1.35-2.20, P < 0.001; GG versus TT: OR = 2.64, 95% CI 1.59-4.39, P < 0.001; GG/GT versus TT: OR = 1.87, 95% CI 1.33-2.62, P < 0.001; GG versus TT/GT: OR = 2.20, 95% CI 1.38-3.51, P = 0.001). Meta-analysis of those two studies on MDM2 rs1690916 polymorphism showed that MDM2 rs1690916 minor allele A was associated with decreased risk of malignant bone tumors (OR = 0.60, 95% CI 0.46-0.77, P < 0.001). Meta-analyses of available data show that there are significant associations of MDM2 SNP309 polymorphism and MDM2 rs1690916 polymorphism with malignant bone tumors.
已有多项研究发表，旨在评估鼠双微体2（MDM2）基因多态性与恶性骨肿瘤风险之间的关联，但这些研究报告的结果相互矛盾，未能证实存在强而一致的关联。为了评估关于MDM2基因多态性与恶性骨肿瘤风险关联的证据，我们对流行病学研究进行了一项荟萃分析。合并的比值比（OR）及其95%置信区间（95%CI）用于评估这些可能的关联。最终，共有3958名个体的四项研究被纳入荟萃分析。对两项关于MDM2 SNP309多态性的研究进行荟萃分析表明，MDM2 SNP309多态性与恶性骨肿瘤风险增加相关（G对T：OR = 1.72，95%CI 1.35 - 2.20，P < 0.001；GG对TT：OR = 2.64，95%CI 1.59 - 4.39，P < 0.001；GG/GT对TT：OR = 1.87，95%CI 1.33 - 2.62，P < 0.001；GG对TT/GT：OR = 2.20，95%CI 1.38 - 3.51，P = 0.001）。对两项关于MDM2 rs1690916多态性的研究进行荟萃分析表明，MDM2 rs1690916次要等位基因A与恶性骨肿瘤风险降低相关（OR = 0.60，95%CI 0.46 - 0.77，P < 0.001）。对现有数据的荟萃分析表明，MDM2 SNP309多态性和MDM2 rs1690916多态性与恶性骨肿瘤存在显著关联。
